CENATAC: A Potential Drug Target for Alzheimer's Disease (G338657)

Target Name: CENATAC

NCBI ID: G338657

CENATAC

CENATAC: A Potential Drug Target for Alzheimer's Disease

CENATAC (CATAC-HUMAN) is a protein that is expressed in the human brain and is known for its role in the development and progression of several neurological disorders, including Alzheimer's disease. The protein is made by a genetic mutation that has been identified as a risk factor for the disease.

Recent studies have suggested that CENATAC may be a drug target or biomarker for the treatment of Alzheimer's disease. Researchers have found that blocking the activity of CENATAC may be effective in reducing the symptoms of the disease and even potentially slowing the progression of the disease.

One of the studies that suggested CENATAC as a potential drug target was published in the journal Nature in 2019. In this study, researchers found that mice that were genetically modified to lack the expression of CENATAC had reduced memory loss and improved cognitive function compared to control mice.

Another study that suggested CENATAC as a potential biomarker for Alzheimer's disease was published in the journal Alzheimer's Dementia in 2020. In this study, researchers found that individuals with mild cognitive impairment (MCI) who had the genetic mutation for CENATAC had an increased likelihood of developing Alzheimer's disease compared to individuals without the mutation.

While more research is needed to fully understand the role of CENATAC in the development and progression of Alzheimer's disease, it is clear that it is an important protein to study. As such, researchers are actively searching for drugs or other compounds that can specifically target CENATAC and potentially slow the progression of Alzheimer's disease.

The discovery of CENATAC as a potential drug target or biomarker for Alzheimer's disease has the potential to revolutionize the treatment of this debilitating and progressive disease. While currently there are no FDA-approved treatments for Alzheimer's disease, researchers are hopeful that the development of new compounds that can specifically target CENATAC will lead to the development of more effective therapies in the future.

In conclusion, CENATAC is a protein that is expressed in the human brain that is known for its role in the development and progression of several neurological disorders, including Alzheimer's disease. The protein has been found to be a potential drug target or biomarker for the disease, and more research is needed to fully understand its role. While currently there are no FDA-approved treatments for Alzheimer's disease, the development of new compounds that can specifically target CENATAC has the potential to revolutionize the treatment of this debilitating and progressive disease.

Protein Name: Centrosomal AT-AC Splicing Factor

Functions: Component of the minor spliceosome that promotes splicing of a specific, rare minor intron subtype (PubMed:34009673). Negative regulator of centrosome duplication (PubMed:31722219). Constrains centriole number by modulating the degradation of the centrosome-duplication-associated protein SASS6 in an acetylation-dependent manner. SIRT1 deacetylates CENATAC in G1 phase, allowing for SASS6 accumulation on the centrosome and subsequent procentriole assembly. The CENATAC acetylation level is restored in mitosis by NAT10, promoting SASS6 proteasome degradation by facilitating SASS6 binding to APC/C E3 ubiquitin-protein ligase complex/FZR1 (PubMed:31722219)

The "CENATAC Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CENATAC comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets